anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
A substantially non-aqueous aerosol insecticidal and/or bactericidal and/or fungicidal and/or insect repellent spray composition comprises a normally gaseous propellant maintained in liquid phase under pressure in an aerosol container equipped with a spray valve, an insecticidal and/or bactericidal and/or fungicidal and/or insect-repellent ingredient (the "active ingredient") dissolved in said liquid propellent and a powdered material capable of absorbing said active ingredient when dissolved in said propellent, said powdered absorbent material being insoluble in said propellent and adapted to be sprayed from the container by said propellent and to act when so sprayed as a carrier for said active ingredient upon evaporation of the propellent.  The powder may be talc or starch. The active ingredient may be allethrin, pyrethrum plus either sesame oil or piperonyl butoxide, D.D.T., undecylenic acid, oleum vetiveriae, oleum quassiae, or N,N-diethyl-m-toluamide. Optional ingredients include kerosene, thymol, benzoic acid, and perfumes. The propellent may be a fluorinated hydrocarbon.ALSO:A substantially non-aqueous aerosol insecticidal and/or bactericidal and/or fungicidal and/or insect repellent spray composition comprises a normally gaseous propellant maintained in liquid phase under pressure in an aerosol container equipped with a spray valve, an insecticidal and/or bactericidal and/or fungicidal and/or insect repellent ingredient (the "active ingredient") dissolved in said liquid propellant and a powdered material capable of absorbing said active ingredient when dissolved in said propellent, said powdered absorbent material being insoluble in said propellent and adapted to be sprayed from the container by said propellent and to act when so sprayed as a carrier for said active ingredient upon evaporation of the propellent.  The powder may be talc or starch.  The active ingredient may be allethrin, pyrethrum plus either sesame oil or piperonyl butoxide, D.D.T., undecylenic acid, oleum vetiveriae, oleum quassiae, or N,N-diethyl-m-toluamide.  Optional ingredients include kerosene, thymol, benzoic acid, and perfumes.  The propellent may be a fluorinated hydrocarbon.
The present invention discloses an isolated nucleic acid encoding a C-terminal fragment of paratope component 1(PSPC 1). The C-terminal fragment of PSPC1 comprises an extension of greater than 10 but NO more than 131 amino acid residues, wherein its C-terminal amino acid is identical to the C-terminus of the PSPCl sequence SEQ ID NO 3, and exhibits biological activity against tumor cells. Tumor cells are associated with either PSPC1 or protein tyrosine kinase 6(PTK6), or both. The anti-tumor activity is selected from at least: (a) inhibiting tumor cell growth; (b) inhibiting tumor cell progression; (c) inhibiting tumor cell metastasis; (d) reduced PSPC1 expression; and (e) reducing the expression of oncogenic PTK6 in the cytoplasm. The invention also discloses a peptide containing the C-terminal fragment sequence of PSPC 1. The invention also discloses kits and methods for predicting tumor progression, metastasis, and prognosis in cancer patients.
The invention belongs to the technical field of medicine compatibility and preparation processes thereof, and discloses a bacteriostatic and antiperspirant preparation and a preparation method thereof. The preparation is prepared by selecting and using various raw materials with rich conventional resources and applicable curative effect. The raw materials and the solvent in the preparation interact and fuse with each other, so that the effective components contained in the raw materials and the solvent are combined to achieve the effects of disinfection and sterilization, sweat gland secretion excess inhibition, dampness elimination and exterior syndrome relieving. The preparation has effects of resisting pathogenic microorganism and inflammation, and can be used for treating diseases from outside of patient body. The preparation has no toxic and side effects, has strong stability and long service life, and is suitable for patients of all ages. The preparation method of the bacteriostatic antiperspirant has simple operation process flow and low requirements on the precision of a preparation device and the professional performance of operators, can promote the effective components of all raw materials to be separated out, and is suitable for mass production in processing plants.
Endo-antigen extracts of Bordetella pertussis and Bordetella parapertussis are prepd. by (a) culturing separately 2 strains of B. pertussis and one of B. parapertussis in different culture media, (b) extracting the bacteria, (c) lysing the extracted bacteria, (d) centrifuging the lysate and recovering the supernatant liquid, (e) combining the three liquids in equal parts and (f) de-toxifying the endo-antigens in the mixt. The culture is pref. effected in a medium contg. L-cystine and DL-tryptophan. Lysis is pref. effected with glycine, and detoxification is effected with sodium mercurothiolate. The products are used to prepare anti-whooping cough vaccines, to prepare the corresp. anti-serums, to stimulate lymphocytes, and for serological research. The vaccines have less side effects than conventional anti-whooping cough vaccines.
In a 2-year study in Sprague-Dawley rats, albuterol sulfate caused a significant dose-related increase in the incidence of benign leiomyomas of the mesovarium and above dietary doses of 2 mg/kg (approximately equivalent to the maximum recommended daily inhalation dose for Albuterol Sulfate Inhalation Solution on a mg/m 2 basis). In another study, this effect was blocked by the co-administration of propranolol, a non-selective beta-adrenergic antagonist. 

In an 18-month study in CD-1 mice, albuterol sulfate showed no evidence of tumorigenicity at dietary doses up to 500 mg/kg (approximately 140 times the maximum recommended daily inhalation dose of Albuterol Sulfate Inhalation Solution on a mg/m 2 basis). In a 22-month study in Golden hamsters, albuterol sulfate showed no evidence of tumorigenicity at dietary doses up to 50 mg/kg (approximately 20 times the maximum recommended daily inhalation dose of Albuterol Sulfate Inhalation Solution on a mg/m 2 basis). 

Albuterol sulfate was not mutagenic in the Ames test or a mutation test in yeast. Albuterol sulfate was not clastogenic in a human peripheral lymphocyte assay or in an AH 1 strain mouse micronucleus assay. 

Reproduction studies in rats demonstrated no evidence of impaired fertility at oral doses of albuterol sulfate up to 50 mg/kg (approximately 30 times the maximum recommended daily inhalation dose of Albuterol Sulfate Inhalation Solution on a mg/m 2 basis).
Pharmacokinetics: Asacol tablets are coated with an acrylic-based resin that delays release of mesalamine until it reaches the terminal ileum and beyond. This has been demonstrated in human studies conducted with radiological and serum markers. Approximately 28% of the mesalamine in Asacol tablets is absorbed after oral ingestion, leaving the remainder available for topical action and excretion in the feces. Absorption of mesalamine is similar in fasted and fed subjects. The absorbed mesalamine is rapidly acetylated in the gut mucosal wall and by the liver. It is excreted mainly by the kidney as N-acetyl-5-aminosalicylic acid.

Mesalamine from orally administered Asacol tablets appears to be more extensively absorbed than the mesalamine released from sulfasalazine. Maximum plasma levels of mesalamine and N-acetyl-5-aminosalicylic acid following multiple Asacol doses are about 1.5 to 2 times higher than those following an equivalent dose of mesalamine in the form of sulfasalazine. Combined mesalamine and N-acetyl-5-aminosalicylic acid AUC's and urine drug dose recoveries following multiple doses of Asacol tablets are about 1.3 to 1.5 times higher than those following an equivalent dose of mesalamine in the form of sulfasalazine.

The tmax for mesalamine and its metabolite, N-acetyl-5-aminosalicylic acid, is usually delayed, reflecting the delayed release, and ranges from 4 to 12 hours. The half-lives of elimination (t1/2elm) for mesalamine and N-acetyl-5-aminosalicylic acid are usually about 12 hours, but are variable, ranging from 2 to 15 hours. There is a large intersubject variability in the plasma concentrations of mesalamine and N-acetyl-5-aminosalicylic acid and in their elimination half-lives following administration of Asacol tablets.
Various implementations disclosed herein include devices, systems, and methods for tailoring information regarding a pharmaceutical article to user types. In various implementations, a device includes a non-transitory memory and a processor coupled with the non-transitory memory. In some implementations, a method includes obtaining a request to synthesize a plurality of pharmaceutical content items for respective user types. In some implementations, the plurality of pharmaceutical content items provides information regarding a pharmaceutical article. In some implementations, the method includes determining, for the respective user types, corresponding expected engagement values indicative of expected engagement with the subject. In some implementations, the method includes determining, based on the corresponding expected engagement values, respective content templates for the plurality of pharmaceutical content items. In some implementations, the method incudes synthesizing the plurality of pharmaceutical content items by populating the respective content templates with information regarding the pharmaceutical article.
The STAR Trial is a prospective, randomized, multi-center device trial intended to assess safety and efficacy of subcutaneous administration of Celution processed ADRCs into fingers of patients with hand dysfunction due to scleroderma.

Following informed consent and screening evaluations, eligible subjects will undergo pre-operative testing. Subjects will then undergo fat harvest through small volume liposuction under local anesthesia. Lipoaspirate will be processed in the Celution System to isolate and concentrate ADRCs for immediate subcutaneous administration under local anesthesia. Subjects will be randomly assigned to receive ADRCs (40 million cells) or a visually-matched placebo in a 1:1 ratio. All subjects will receive subcutaneous administration of test substance (ADRC or placebo) into all fingers of both hands. Following completion of all 48 week visits and database lock, placebo treated subjects will be offered treatment with their ADRCs cells should they continue to qualify according to the inclusion/exclusion criteria and should they wish to be treated with ADRCs and agree to the fat harvest procedure.
The control condition concerns the treatment-as-usual (TAU) that consists in routine care that patients receive when they are diagnosed with major depression in primary care. We will not interfere with treatments delivered in TAU, but the intervention will be tracked (e.g., medication). The psychiatrist of our team will monitor possible medicine intake (stabilized throughout the trial). 50 patients will be integrated in this condition.
Endoscopic ultrasound (EUS) is paramount in the diagnosis and evaluation of cancers involving the gastrointestinal tract. EUS allows for the acquisition of cellular (fine needle aspirate - FNA) or tissue biopsy (fine needle biopsy - FNB) for diagnostic purposes. This has traditionally been done with fine needle aspirate where a needle is inserted into the tumor and potentially malignant cells are extracted for microscopic analysis. More recently, a needle that allows a tissue biopsy for histologic analysis has been FDA approved.

We will compare tissue samples obtained by standard FNA to FNB with a sample size of 140 patients with the primary outcome being diagnostic yield. Each patient will be randomized to FNA or FNA. If after 3 passes the on-site evaluation remains inadequate, the endoscopist will crossover to the other arm.
Participants will receive pertuzumab 840 milligrams (mg) (loading dose) and 420 mg (maintenance dose) intravenous (IV) infusion followed by trastuzumab 8 milligrams per kilogram (mg/kg) (loading dose) and 6 mg/kg (maintenance dose) IV infusion followed by docetaxel 75 milligrams per square meter (mg/m\^2) IV infusion and carboplatin at a dose to achieve an area under the curve (AUC) of 6 milligrams per milliliter\* minute (mg/mL\*min) IV infusion every 3 weeks (q3w) for 6 cycles in neoadjuvant period. Participants will receive pertuzumab 840 mg (loading dose) and 420 mg (maintenance dose) IV infusion followed by trastuzumab 8 mg/kg (loading dose) and 6 mg/kg (maintenance dose) IV infusion q3w for rest of the cycles (12 cycles) in adjuvant period (up to a total of 18 cycles).
A 29-year-old man from Comoros presented with rapidly progressive paraplegia and sexual dysfunction. Magnetic resonance imaging (MRI) showed a contrast-enhanced conus medullaris lesion. Differential diagnoses included tumors, abscesses, and inflammatory diseases. Neurosurgery was delayed to complete examinations. Cerebral MRI showed three abscesses. Body computed tomography scan showed supracentimetric polyadenopathies, pulmonary nodules, prostatic lesion, and enhanced seminal vesicle, with hypermetabolism on positron emission tomography with 2-deoxy-2-[fluorine-18]fluoro-D-glucose scan. Histology of lymph node biopsy showed granulomatous infiltration without acid-fast bacilli, and positive polymerase chain reaction for Mycobacterium tuberculosis. Lymph node culture was positive after 2 months, urine culture after 3 weeks, but cerebrospinal fluid and sputum cultures were negative. A 1-year antituberculosis therapy was initiated, associated with corticosteroids because the patient developed tuberculosis-immune reconstitution syndrome, revealed by the recurrence of neurological symptoms. After 2 months the patient completely recovered and could run. MRI showed stability of the voluminous tuberculoma with decrease of medullary edema. Avoiding surgery in those cases may prevent iatrogenic neurological deterioration.
A method for encapsulation of antineoplastic agents in liposome is provided, having preferably a high drug:lipid ratio. Liposomes may be made by a process that loads the drug by an active mechanism using a transmembrane ion gradient, preferably a transmembrane pH gradient. The liposome compositions may be prepared by first forming the liposomes in a first aqueous medium, preferably a buffer, then acidifying or alkalinizing the medium thereby establishing a pH gradient, and then admixing the acidified or alkalinized liposomes with the antineoplastic agent. Using this technique, trapping efficiencies approach 100 %, and liposome may be loaded with drug immediately prior to use, eliminating stability problems related to drug retention. Drug:lipid ratios employed are about 3-80 fold higher than for traditional liposome preparations, and the release rate of the drug from the liposomes is reduced. The liposome compositions may be dehydrated and later rehydrated, and may be used in combination with a pharmaceutically acceptable carrier or diluent. An assay method to determine free antineoplastic agents in a liposome preparation is also disclosed.
Participants will be using closed loop control (CLC) with adaptive biobehavioral control (ABC) for 16 weeks. Participants will then use closed loop control (CLC) with behavioral adaptation module (BAM) for 4 weeks, followed by closed loop control (CLC) for 2 weeks.
Patients will receive acalabrutinib for a minimum of 13 cycles and maximum 26 cycles and Obinutuzumab will be administered during Cycles 2-7. This will be followed by treatment-free observation through the 65th cycle. Patients who progress during the observation period, per iwCLL criteria, will receive 13 cycles of acalabrutinib in combination with obinutuzumab in the retreatment phase of this study.
Each active hidradenitis suppurativa lesion will be injected with up to 1 mL of sodium chloride 0.9% in up to 3 anatomic areas. The maximum treatment volume is 3 mL.
Myxofibrosarcoma (MFS) is a common soft tissue sarcoma of the elderly that typically shows low tumor mutational burden, with mutations in TP53 and in genes associated with cell cycle checkpoints ( RB1 , CDKN2A ). Unfortunately, no alterations or markers specific to MFS have been identified and, as a consequence, there are no effective targeted therapies. The receptor tyrosine kinase AXL, which drives cellular proliferation, is targetable by new antibody-based therapeutics. Expression of AXL messenger RNA is elevated in a variety of sarcoma types, with the highest levels reported in MFS, but the pathogenic significance of this finding remains unknown. To assess a role for AXL abnormalities in MFS, we undertook a search for AXL genomic alterations in a comprehensive genomic profiling database of 463,546 unique tumors (including 19,879 sarcomas, of which 315 were MFS) interrogated by targeted next-generation DNA and/or RNA sequencing. Notably, the only genomic alterations recurrent in a specific sarcoma subtype were AXL W451C (n = 8) and AXL W450C (n = 2) mutations. The tumors involved predominantly older adults (age: 44 to 81 [median: 72] y) and histologically showed epithelioid and spindle-shaped cells in a variably myxoid stroma, with 6 cases diagnosed as MFS, 3 as undifferentiated pleomorphic sarcoma (UPS), and 1 as low-grade sarcoma. The AXL W451C mutation was not identified in any non-sarcoma malignancy. A review of publicly available data sets revealed a single AXL W451C-mutant case of UPS that clustered with MFS/UPS by methylation profiling. Functional studies revealed a novel activation mechanism: the W451C mutation causes abnormal unregulated dimerization of the AXL receptor tyrosine kinase through disulfide bond formation between pairs of mutant proteins expressing ectopic cysteine residues. This dimerization triggers AXL autophosphorylation and activation of downstream ERK signaling. We further report sarcomas of diverse histologic subtypes with AXL gene amplifications, with the highest frequency of amplification identified in MFS cases without the W451C mutation. In summary, the activating AXL W451C mutation appears highly specific to MFS, with a novel mechanism to drive unregulated signaling. Moreover, AXL gene amplifications and messenger RNA overexpression are far more frequent in MFS than in other sarcoma subtypes. We conclude that these aberrations in AXL are distinct features of MFS and may aid diagnosis, as well as the selection of available targeted therapies.
The invention discloses a medicine for treating diabetes. The medicine is a Tibetan medicine, is also called Jiumei No. 2 thirst quenching and blood sugar reducing tea and is composed of an active component or the active component and pharmaceutically acceptable accessories, wherein, the active component is prepared from mango kernel, rose apple, semen caesalpinia crista, semen punicae granati and bear gall powder according to a certain weight ratio. The medicine can be made into any general dosage form for oral administration. The medicine provided in the invention has the functions of nourishing lung, clearing stomach, tonifying yin, moisturizing dryness, generating body fluid and quenching thirst, and can be used for treating diabetes. In Tibetan medicine, the medicine is applicable to diabetes symptoms caused by disorder of Chiba, e.g., polydipsia, polyphagia, polyuria, macies, urine sugar and elevation of blood sugar levels. In traditional Chinese medicine, the medicine is applicable to diabetes caused by deficiency of both qi and yin, and symptoms of such kind of diabetes comprises polydipsia, polyphagia, polyuria, macies, lasstitude, numbness and aching of limbs, giddy tinnitus, spontaneous sweating, dry stools, rolling pulse, urine sugar, elevation of blood sugar levels, etc.
Disclosed is a method for identifying compounds that bind to or modulate a glutamate transporter. The disclosed method is useful for identifying compounds that can inhibit, stimulate, or modulate the activity of the glutamate transporter and thus affect glutamate reuptake. The method is a screening technique where compounds known to bind to glutamate receptors (for example, glutamate receptor ligands, including many agonists, and antagonists) are bound to a glutamate transporter and compounds are screened to identify those that can after the binding of the glutamate receptor-binding compounds.  Compounds shown to alter the binding of the receptor-binding compounds.  Compounds shown to alter the binding of the receptor compounds from glutamate transporter in the disclosed assay can have a variety of effects on glutamate transporter in the disclosed assay can have a variety of effects on glutamate transporter activity including activation or inhibition. These compounds are expected to affect or interfere with glutamate reuptake by the glutamate transporter and thus can be used to modulate, stimulate, or inhibit glutamate reuptake. Such compounds are useful to treat various neurological diseases and conditions involving glutamate transporter and glutamate receptor activation.  One of the compounds is (2S,4R-4-methylgutamate or [3H]-(2S,4R-4-methylglutamate. For example, excess extracellular glutamate is a cause of excessive activation of glutamate receptors. Stimulating glutamate reuptake by glutamate transporter can ameliorate excessive activation of glutamate receptors by reducing the extracellular glutamate concentration. Prodrug forms of transporter compounds are preferred for use as drugs.
Respiratory syncytial virus (RSV) is associated with considerable morbidity and mortality among older adults (aged ≥60 years) and adults with certain chronic conditions in the United States (US). Despite this burden, no previous studies have assessed the knowledge, attitudes, and perceptions (KAP) of RSV among these populations. This study evaluates RSV-related KAP among US adults at increased risk of severe RSV infection. A cross-sectional, web-based survey was administered from May to June 2022 to better understand respiratory infection- and RSV-related KAP among US adults who are at risk of severe RSV infection. The survey included ≥200 adults in each of 4 subgroups: adults aged 60-89 years, and adults aged 18-59 years with ≥1 chronic cardiovascular condition, chronic pulmonary condition, or diabetes mellitus. Survey responses were analyzed descriptively overall and by subgroup, with exploratory logistic regression modeling used to evaluate characteristics associated with RSV awareness and concern. Among the 827 survey respondents, only 43.3% had ever heard of RSV (n = 358/827). The study identified key knowledge gaps (e.g. bacterial vs. viral nature of respiratory infections, RSV seasonality, common RSV symptoms, extent to which RSV causes respiratory infections in specific patient populations). Although 33.7% of RSV-aware adults (n = 120/356) reported being worried/very worried about RSV, 67.3% (n = 241/358) rarely consider RSV as a potential cause of their cold/flu-like symptoms. Results from this study highlight important knowledge gaps related to RSV, perceived risk, and severity of RSV. Findings can be used to support the development of tailored education efforts to support RSV prevention.